WEKO3
アイテム
{"_buckets": {"deposit": "6c64fefd-af5c-404b-baee-7d0efd9439d3"}, "_deposit": {"created_by": 14, "id": "8144", "owners": [14], "pid": {"revision_id": 0, "type": "depid", "value": "8144"}, "status": "published"}, "_oai": {"id": "oai:sapmed.repo.nii.ac.jp:00008144", "sets": ["1907"]}, "author_link": ["6665", "6666", "6667", "6668", "6669"], "item_2_alternative_title_18": {"attribute_name": "その他のタイトル", "attribute_value_mlt": [{"subitem_alternative_title": "Chemotherapy with Temozolomide in Patients with Malignant Glioma at First Relapse"}]}, "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2007-03-01", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "28", "bibliographicPageStart": "23", "bibliographicVolumeNumber": "17", "bibliographic_titles": [{"bibliographic_title": "北海道脳神経疾患研究所医誌 = Journal of Hokkaido Brain Research Foundation"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Temozolomide is an alkylating agent that has demonstrated clinical antitumor activity and a relatively well-tolerated safety profile in patients with various advanced cancers, including malignant gliomas. We report the antitumor efficacy and safety profile of temozolomide in patients with malignant glioma at first relapse. Nineteen patients with astrocytic tumors (anaplastic oligoastrocytoma [AOA] : 2, anaplastic astrocytoma [AA] : 10, glioblastoma [GB] : 7) were treated. Median age was 50 years. Patients were treated with temozolomide 200 mg/m2/day. Patients previously treated with chemotherapy received temozolomide 150 mg/m2/day ; the dose could be increased to 200 mg/m2/day in the absence of grade 3/4 toxicity. Therapy was administered orally on the first 5 days of a 28-day cycle. Progression-free survival (PFS) at 6 months was 60%. The median PFS was 6.2 months. The median overall survival was 9 months. The objective response rate was 26% (5% complete response [CR], 21% partial response [P11]), with an additional 37% of patients with stable disease (SD). Adverse events were mild to moderate, with hematologic side effects occurring in 15% of patients. Temozolomide demonstrated good single-agent activity, an acceptable safety profile, and documented health-related quality of life benefits in patients with recurrent malignant glioma.", "subitem_description_type": "Abstract"}]}, "item_2_identifier_60": {"attribute_name": "URI", "attribute_value_mlt": [{"subitem_identifier_type": "URI", "subitem_identifier_uri": "http://ir.cc.sapmed.ac.jp/dspace/handle/123456789/846"}]}, "item_2_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "中村記念病院"}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1340-5764", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "佐藤, 憲市"}], "nameIdentifiers": [{"nameIdentifier": "6665", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "伊東, 民雄"}], "nameIdentifiers": [{"nameIdentifier": "6666", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "尾崎, 義丸"}], "nameIdentifiers": [{"nameIdentifier": "6667", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "及川, 光照"}], "nameIdentifiers": [{"nameIdentifier": "6668", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "中村, 博彦"}], "nameIdentifiers": [{"nameIdentifier": "6669", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2018-07-21"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "n1340576417123.pdf", "filesize": [{"value": "1.6 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_note", "mimetype": "application/pdf", "size": 1600000.0, "url": {"label": "n1340576417123.pdf", "url": "https://sapmed.repo.nii.ac.jp/record/8144/files/n1340576417123.pdf"}, "version_id": "ac3dee55-4838-46e2-87c5-745d8e0966fc"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "temozolomide", "subitem_subject_scheme": "Other"}, {"subitem_subject": "chemotherapy", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "malignant glioma", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "再発悪性神経膠腫に対するTemozolomideの治療成績", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "再発悪性神経膠腫に対するTemozolomideの治療成績", "subitem_title_language": "ja"}]}, "item_type_id": "2", "owner": "14", "path": ["1907"], "permalink_uri": "https://sapmed.repo.nii.ac.jp/records/8144", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2009-03-24"}, "publish_date": "2009-03-24", "publish_status": "0", "recid": "8144", "relation": {}, "relation_version_is_last": true, "title": ["再発悪性神経膠腫に対するTemozolomideの治療成績"], "weko_shared_id": -1}
再発悪性神経膠腫に対するTemozolomideの治療成績
https://sapmed.repo.nii.ac.jp/records/8144
https://sapmed.repo.nii.ac.jp/records/8144dca9410b-358e-4d1a-a6db-a0ddcc642b1e
名前 / ファイル | ライセンス | アクション |
---|---|---|
n1340576417123.pdf (1.6 MB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2009-03-24 | |||||
タイトル | ||||||
言語 | ja | |||||
タイトル | 再発悪性神経膠腫に対するTemozolomideの治療成績 | |||||
言語 | ||||||
言語 | jpn | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | temozolomide | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | chemotherapy | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | malignant glioma | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
佐藤, 憲市
× 佐藤, 憲市× 伊東, 民雄× 尾崎, 義丸× 及川, 光照× 中村, 博彦 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Temozolomide is an alkylating agent that has demonstrated clinical antitumor activity and a relatively well-tolerated safety profile in patients with various advanced cancers, including malignant gliomas. We report the antitumor efficacy and safety profile of temozolomide in patients with malignant glioma at first relapse. Nineteen patients with astrocytic tumors (anaplastic oligoastrocytoma [AOA] : 2, anaplastic astrocytoma [AA] : 10, glioblastoma [GB] : 7) were treated. Median age was 50 years. Patients were treated with temozolomide 200 mg/m2/day. Patients previously treated with chemotherapy received temozolomide 150 mg/m2/day ; the dose could be increased to 200 mg/m2/day in the absence of grade 3/4 toxicity. Therapy was administered orally on the first 5 days of a 28-day cycle. Progression-free survival (PFS) at 6 months was 60%. The median PFS was 6.2 months. The median overall survival was 9 months. The objective response rate was 26% (5% complete response [CR], 21% partial response [P11]), with an additional 37% of patients with stable disease (SD). Adverse events were mild to moderate, with hematologic side effects occurring in 15% of patients. Temozolomide demonstrated good single-agent activity, an acceptable safety profile, and documented health-related quality of life benefits in patients with recurrent malignant glioma. | |||||
書誌情報 |
北海道脳神経疾患研究所医誌 = Journal of Hokkaido Brain Research Foundation 巻 17, 号 1, p. 23-28, 発行日 2007-03-01 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1340-5764 | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
その他のタイトル | ||||||
その他のタイトル | Chemotherapy with Temozolomide in Patients with Malignant Glioma at First Relapse | |||||
出版者 | ||||||
出版者 | 中村記念病院 |